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1. Introduction 
Metastatic spread is achieved through changes in the tissue microenvironment driven by 
tumor cells that allow the formation of various dissemination routes using a variety of 
mechanisms; such as angiogenesis and vasculogenesis (hematogeneous routes), 
lymphangiogenesis (lymphatic routes), and in some particular cases like melanoma, 
vasculogenic mimicry (vasculogenic channels lined by melanoma cells) (Carmeliet, 2005; 
Hendrix et al., 2003; Kopp et al., 2006; Tammela and Alitalo, 2010). Building of dissemination 
routes has to be coordinated with the acquisition of new capabilities by tumor cells that 
enable them to locally invade, intravasate into dissemination channels, survive in the 
circulation, extravasate, and ultimately adapt to a foreign territory. All this complex cascade 
of events is orchestrated by multiple cell types and diverse families of factors and signaling 
circuits controlling intracellular as well as intercellular key communication events (Nguyen 
et al., 2009b). 
Interestingly, a particular subset of extracellular factors have the dual capacity to 
simultaneously impinge on the formation of the dissemination routes and to modulate 
many of the properties that the tumor cells themselves have to acquire in order to fulfill all 
steps required to successfully colonize a foreign territory starting from a primary lesion in a 
drastically different environment. This chapter focuses on an angiostatic factor, pigment 
epithelium derived factor (PEDF), with a broader function in melanoma that allows it to 
dually impinge on destroying some of the more relevant dissemination routes and on 
counteracting key tumor cell properties that enable the metastatic spread of melanoma cells. 
Understanding of the molecular and cellular mechanisms controlling melanoma progression 
has become an active field of research over the last five years unveiling a complex 
intertwined relationship between melanoma cells and the diverse cell types present in the 
tumor microenvironment, as well as a number of key molecular mediators (Shackleton and 
Quintana, 2010; Villanueva and Herlyn, 2008). Plasticity of melanoma cells allows them for 
appropriate reprogramming underlying the decision making process that arbitrates 
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proliferation and migration as mutually exclusive cellular responses that need to alternate in 
the course of tumor progression (Hendrix et al., 2007; Hoek et al., 2008). We have recently 
interrogated the role of PEDF, an angiostatic factor produced at high levels by skin 
melanocytes, in controlling the switch between proliferative and invasive states of 
melanoma cells and its contribution to restrict the metastatic cascade. Our results 
demonstrate that loss of PEDF expression enables melanoma cells to acquire an invasive 
state and therefore its reprogramming is critical for the malignant progression of melanoma 
(Orgaz et al., 2009). 
2. Angiogenesis and melanoma. The role of endogenous inhibitors of 
angiogenesis  
As in every tissue of our body angiogenesis is finely tuned in the skin by the balance of 
endogenous angiogenic growth factors and endogenous angiogenic inhibitors (Jimenez and 
Volpert, 2001). Although the pattern of skin vascularization established during development 
renders the skin a mildly hypoxic microenvironment (pO2 in the dermal/epidermal 
junctions ranging from 0.5% to 10%) (Bedogni and Powell, 2009), a number of physiological 
processes like skin wound healing and cycles of hair follicle growth, and an increasingly 
recognized number of cutaneous pathologies (Laquer et al., 2009; Nguyen et al., 2009a) 
require new vessel formation to respectively achieve proper tissue homeostasis in 
physiological contexts or to chronically activate angiogenesis in the pathological settings. 
Angiogenesis is a hallmark of cancer and it is of significant relevance for the life threatening 
stage of the disease, the metastatic spread (Hanahan and Weinberg, 2000; Hanahan and 
Weinberg, 2011). Angiogenesis is a pivotal process required to effectively deliver oxygen 
and nutrients and to eliminate waste products in lesions beyond 1-2mm of diameter 
(Folkman, 2006). Unlimited growth of primary lesions, activation of dormant 
micrometastases (Goss and Chambers, 2010), as well as the growth of micrometastases to 
macrometastases (Gao et al., 2008), all require neovascularization. The so called tumor 
angiogenic switch refers to the mechanisms responsible for shifting the balance toward 
predominance of angiogenic growth factors accompanied by loss of angiogenesis inhibitors. 
Activation of tumor angiogenic switch triggers the transition from the avascular to the 
vascular phase of tumor growth, which is characterized by uncontrolled, excessive and 
aberrant neovascularization. The vascular phase sustains unlimited neoplastic growth and 
provides diverse vascular routes for the metastatic dissemination of the primary lesion. 
There is significant evidence supporting that cancer metastasis can be determined by the 
angiogenic potential of the primary tumor cells (Kerbel, 2008). Also, preclinical studies using 
mouse models, as well as clinical studies using biopsies have shown that there is a direct 
association between incidence of metastases and the microvascular density in vascular hot 
spots in the tumor periphery (Nico et al., 2008). 
Based on the relevance of tumor neovascularization for the progression of the disease and 
patient outcome, there has been over the last four decades an explosion of the cellular and 
molecular knowledge of the mechanisms and key molecules involved in the creation of the 
diverse types of vessels networks that allow for tumor cell dissemination. All this 
knowledge also led to a rapid and fruitful translation to the clinic of the first generation of 
antiangiogenic drugs (Ellis and Hicklin, 2008; Ferrara and Kerbel, 2005; Jain, 2008; Jubb et al., 
2006; Loges et al., 2009; Orgaz et al., 2008) which have been used up to now in the context of 
advanced disease and as a general rule in combination with a wide range of 
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chemotherapeutic agents or radiation therapy. Also, the general principle of antiangiogenic 
therapy of cancer in the clinic has been almost exclusively based on the use of single 
antiangiogenic agents or drugs. Although most of these studies have obtained reasonably 
encouraging results, further evaluation of more complex therapeutic regimens targeting 
simultaneously multiple angiogenesis pathways should be warranted in patients with 
advanced melanoma and other cancers; or when required to overcome resistance to first line 
antiangiogenic drugs (Bergers and Hanahan, 2008). Notwithstanding, the broad armory of 
identified antiangiogenic drugs should allow designing optimum combinations of 
antiangiogenic drugs that hopefully will be: (i) more efficient and of greater benefit for each 
particular type of cancer, (ii) used as second line antiangiogenic therapies in cases of 
resistance to first line antiangiogenic drugs, or (iii) useful to suitably design the most likely 
effective strategy considering the characteristics of each patient’s type of tumor vascular 
bed. 
The mildly hypoxic microenvironment of the skin significantly contributes to melanocyte 
transformation, as the result of hypoxia effects promoting both proliferation and survival. 
Thus, hypoxia has emerged as a relevant tumor-promoting environmental factor in 
melanoma (Bedogni and Powell, 2009). Additionally, hypoxia is one of the main regulators 
of angiogenic growth factors and angiogenic inhibitors, which contributes to tilt the balance 
toward inducers of angiogenesis and to impose the loss of relevant angiostatic factors 
during tumor progression (Rey and Semenza, 2010). 
Studies with human melanoma xenograft models in nude mice as well as with human 
melanoma biopsies demonstrated that melanoma cells are an important source of 
angiogenic growth factors like vascular endothelial growth factor (VEGF), basic fibroblast 
growth factor (bFGF), placenta growth factor (PlGF), transforming growth factors-α and β 
(TGF- α and β), platelet derived growth factor-B (PDGF-B) and interleukin-8 (IL-8), among 
others (Basu et al., 2009; Mahabeleshwar and Byzova, 2007). A number of studies have 
correlated melanoma neovascularization with poor patient prognosis, overall survival, 
ulceration and increase rate of relapse; as it is the case in many other types of cancers (Ria et 
al., 2010). However, production of angiogenesis inhibitors by melanoma cells and their 
regulation in the course of melanoma progression has remained poorly explored. 
We have recently focused on the study of the angiostatic factor pigment epithelium derived 
factor (PEDF) in human melanocytes and melanoma progression (Fernandez-Garcia et al., 
2007; Garcia et al., 2004; Orgaz et al., 2009). PEDF was originally described as the most potent 
angiostatic factor in the eye that plays a relevant role in ensuring the correct pattern of 
vascularization of diverse eye compartments (Bouck, 2002). PEDF is produced at high levels 
by retinal pigment epithelial (RPE) cells, and it counteracts a number of potent angiogenic 
growth factors in the retina like VEGF, insulin growth factor-1 (IGF-1), bFGF, etc; ensuring 
the right balance of angiogenic regulators that leads to an optimum physiological pattern of 
blood vessels for correct retinal function. Importantly, avascular eye compartments like the 
vitreous and cornea are rich in PEDF. To further support the relevance of PEDF in the eye, a 
number of eye pathologies like diabetic retinopathy and eye related macular degeneration 
are associated with loss of PEDF expression and therefore predominance of the action of 
angiogenic growth factors, leading to excessive and aberrant vascularization patterns 
associated with loss of vision (Tombran-Tink, 2010). 
We have recently shown that melanocytes are also among the cell types in our body that 
produce and secrete the highest levels of PEDF (Orgaz et al., 2009), which are comparable to 
the levels produced by RPE cells, neural cells or retinoblastoma cells. However, endothelial 
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cells, one of the main targets of PEDF’s action, produce very low levels of this angiostatic 
factor and therefore rely on other cell types to bring PEDF to many scenarios where proper 
tissue homeostasis requires halting the angiogenic cascade to render the vasculature to a 
quiescent state. If PEDF is highly produced by melanocytes the following questions arise: (i) 
is there an autocrine role of PEDF on pigment cells? It has been recently described that 
PEDF is stored in melanosomes, although its putative role in the regulation of pigment 
production and secretion remains to be explored (Chi et al., 2006). Furthermore, PEDF 
directly modulates the proliferative and migratory capability of normal melanocytes (Orgaz 
et al., 2009), (ii) is PEDF expression regulated during melanoma progression?, and which are 
the functional consequences of its modulation? Our insights about these questions will be 
addressed in the following section. 
Primary melanoma biopsies are characterized by high PEDF expression in the vast majority 
of human biopsies analyzed, although a significant degree of heterogeneity exists (Orgaz et 
al., 2009; and unpublished data). Conversely, PEDF expression is lost in cutaneous 
metastases of human melanoma (Orgaz et al., 2009). 
When is angiogenesis switched on during melanoma progression and its relevance for the 
metastatic spread of human melanoma is still a matter of certain debate (Basu et al., 2009; 
Helfrich et al., 2010). Lack of consensus most probably reflects difficulty on adequately 
defining staging and progression of melanoma, together with limitations of currently available 
models to explain how melanoma evolves and malignizes (see Section 3.1). It seems plausible 
that acquisition of angiogenic potential and increase in microvascular density occur 
gradually as melanoma lesions progress from the radial growth phase (RGP) to the vertical 
growth phase (VGP) and to the metastatic phase (M). In our studies we found that the most 
dramatic regulation of PEDF levels corresponds to the transition from primary melanoma to 
cutaneous metastases of melanoma (described in more detail in Section 3.3). Also most likely 
melanomas progressively develop a more profuse network of blood vessels from RGP to 
VGP, but due to the extreme heterogeneity of human melanoma biopsies we were unable to 
find important differences on the level of PEDF when comparing RGP to VGP biopsies, 
although there was a tendency to a decrease from RGP to VGP (unpublished data). 
We have directly explored by means of global gene expression analysis using microarrays 
the consequences of PEDF overexpression on the angiogenic potential of human melanoma 
cells. Importantly, exogenous PEDF overexpression abrogates the ability of aggressive 
melanoma cells to produce potent angiogenic growth factors like VEGF or IL-8, tilting the 
balance toward inhibition of melanoma angiogenesis (Orgaz et al., 2011). Given the role of 
VEGF and IL-8 as highly potent angiogenic growth factors in melanoma, together with their 
role in directly promoting melanoma cell migration and invasion; the abrogation of their 
production by melanoma cells upon PEDF’s action is of special relevance. Additionally, both 
VEGF and IL-8 increase vascular permeability and therefore, by eliminating these 
angiogenic growth factors PEDF normalizes to a certain extent tumor vascular leakiness and 
thereby impedes melanoma intravasation/extravasation. Finally, a number of extracellular 
matrix proteins (like collagen IV A2 (COL4A2) and fibronectin 1 (FN1)), matrix enzymes 
and matrix metalloproteinases (such as tissue inhibitors of metalloproteinases (TIMPs), a 
disintegrin and metalloproteinase domain (ADAMs), a disintegrin-like and metalloprotease 
(reprolysin type) with thrombospondin type 1 motif (ADAMTs)) or serine (or cysteine) 
proteinase inhibitor (SERPINs) and integrins (like integrin β3) relevant in different steps of 
the angiogenic cascade were modulated by PEDF, with a trend corresponding to halting the 
angiogenic process (Orgaz et al., 2011). 
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Finally, as melanoma cells become more aggressive they acquire the ability to mimic 
molecularly and functionally the endothelial cells. This specific reprogramming, characteristic 
of highly aggressive melanoma cells, is called vasculogenic mimicry, and endows them with 
the ability to form vascular channels lined by melanoma cells; which represent a unique 
escape route for the spread of melanoma (Hess et al., 2007). We found that PEDF is able to 
impede the formation of melanoma vasculogenic channels in the lungs of nude mice in 
colonization assays of human melanoma cell lines (Orgaz et al., 2009); which adds another 
mechanism of antimetastatic action for this multifunctional factor. The molecular basis by 
which PEDF abrogates melanoma vasculogenic mimicry are still unknown and would be 
extremely interesting to explore in view of the relevance of this mechanism in the context of 
melanoma dissemination. 
Another relevant aspect of the tumor vasculature that distinguishes it from normal 
vasculature is the degree of vessel maturation (Baluk et al., 2005; Jain, 2003). Over the last 
decades it was demonstrated that the efficacy of antiangiogenic strategies in solid tumors is 
inversely correlated to the degree of maturation of the tumor vascular bed (Helfrich and 
Schadendorf, 2011; Jimenez and Volpert, 2001). This was the case not only for strategies 
based on interference with angiogenic growth factors and their receptors, but also for 
angiostatic factors like PEDF. We demonstrated that PEDF only induces vessel regression of 
immature vessels poorly covered by pericytes, while those tumor vessels that are covered 
with pericytes over the course of time of tumor establishment remain invulnerable to 
PEDF’s angiostatic action (Garcia et al., 2004). This important mechanistic observation 
opened up the following therapeutic windows: (i) use of antiangiogenic strategies at very 
early stages of tumor progression, when presumably a larger proportion of the vessels are 
still immature; (ii) use of antiangiogenic strategies in tumor types in which the majority of 
vessels remain immature; and (iii) design combination therapies in which antiangiogenic 
strategies directed to endothelial cells are concomitantly used with drugs directed to 
pericytes aimed to destabilize the tumor vasculature by depriving it of the interactions with 
pericytes, and therefore rendering it immature. Notwithstanding the limitation on the 
angiostatic action of PEDF, which is restricted to immature vessels, all direct PEDF’s effects 
on melanoma cells contribute to halt melanoma metastases, and strongly support the 
development of novel therapeutic strategies based on knowledge of the diverse actions of 
this biological modifier of melanoma. 
The mechanism by which PEDF induces immature blood vessel regression has been studied 
in detail over the last years by us and others. A common characteristic in the mechanism of 
action of PEDF and all the endogenous inhibitors of angiogenesis so far described 
(thrombospondin-1, angiostatin, endostatin, canstatin, tumstatin, etc) is that they are capable 
of inducing apoptosis in endothelial cells present in immature, remodeling vessels, thus 
causing selective regression of the expanding aberrant tumor vasculature without affecting 
normal vessels (Jimenez and Volpert, 2001; Volpert, 2000). Angiogenic growth factors like 
VEGF act like essential survival factors in this pathological scenario, but the action of 
endogenous inhibitors of angiogenesis is dominant over that of inducers. PEDF induces 
apoptosis in remodeling endothelial cells by inducing Fas ligand (CD95L) expression on the 
surface of activated endothelial cells via nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFKB) (Aurora et al., 2010; Volpert et al., 2002), which initiates an extrinsic 
cell death cascade. In concert, PEDF hampers endothelial cells survival by reducing the 
expression of pro-survival factor caspase-8 FLICE-inhibitory protein (c-FLIP) through the 
Nuclear Factor of Activated T-cells (NFAT) (Zaichuk et al., 2004). Besides, we have also 
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demonstrated that under stress conditions like serum withdrawal or lack of extracellular 
matrix attachment, PEDF has a certain capacity to induce melanoma cell apoptosis although 
with a weaker potency than in endothelial cells (Garcia et al., 2004). Reduced survival of 
melanoma cells caused by the absence of attachment in the presence of high PEDF 
circulating levels has important consequences for the outcome of tumor cells in transit to the 
metastatic site. 
There are still a number PEDF’s putative actions on the various tumor vascularization 
mechanisms described so far that remain to be explored and that are of critical importance: 
(i) does PEDF affect haematopoyetic precursor cells recruitment?, (ii) does PEDF block 
vasculogenesis (formation of new vessels from endothelial progenitor cells)?, (iii) does PEDF 
induce lymphatic vessels regression? There is no report linking PEDF to vasculogenesis, but 
it has recently been described that PEDF decreases lymph node metastasis of prostate 
cancer, while paradoxically increases extratumoral lymphangiogenesis by unknown 
mechanisms (Halin et al., 2010). 
In the context of spread of the disease an attractive benefit of antiangiogenic strategies is 
their potential to keep micrometastases in a dormant state (Gao et al., 2008; Goss and 
Chambers, 2010). Thrombospondin-1 has been proven to be effective in preventing the 
growth of dormant pulmonary micrometastases in human melanoma xenografts after 
surgical resection or curative radiation of the primary tumor (Rofstad et al., 2004; Rofstad et 
al., 2003). PEDF’s capability to maintain dormant micrometastases in check, preventing their 
growth to macrometastases remains to be evaluated, but it could be of relevant therapeutic 
interest. 
Moreover, it has been shown that PEDF is also produced by a wide variety of epithelial cell 
types in different tissues and its role in controlling primary tumor growth, angiogenesis and 
metastatic spread has been explored in a wide range of tumors using diverse mouse models, 
and analysis of human biopsies. Levels of angiostatic PEDF decrease during the progression 
of a number of cancers, such as hepatocelular carcinoma (Matsumoto et al., 2004), prostate 
cancer (Halin et al., 2004; Qingyi et al., 2009), breast adenocarcinoma (Cai et al., 2006), 
glioblastoma (Guan et al., 2003) and Wilm´s tumors (Abramson et al., 2003). A number of 
recent excellent reviews cover the antitumor and antimetastatic action of PEDF on several 
tumor types (Broadhead et al., 2009; Fernandez-Garcia et al., 2007; Hoshina et al., 2010). 
3. Halting melanoma progression. The role of pigment epithelium-derived 
factor 
3.1 Cutaneous melanoma. Current models of melanoma progression 
Melanoma cells arise from melanocytes, normal cells specialized in the production of 
pigment melanin, which reside in the basal layer of the epidermis, among other locations, 
and whose homeostasis is tightly controlled by epidermal keratinocytes (Gray-Schopfer et 
al., 2007).The classical model of melanoma progression describes melanoma development as 
a series of histopathological steps regarding the thickness and the grade of invasion of the 
lesion (Clark, 1991). Nevi are relatively benign lesions that rarely progress to melanoma, in 
part because most of melanocytes in nevocytic lesions are in a state of senescence-associated 
growth arrest (Michaloglou et al., 2005). RGP, melanomas have high proliferative potential 
but null or very low invasive ability, being confined to the epidermis (Gray-Schopfer et al., 
2007). In contrast, VGP, melanomas are competent for metastasis, fully invade the upper 
part of the epidermis as well as the dermis and the subcutaneous tissue, being able to reach 
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blood or lymph circulation and eventually colonize and develop secondary tumors at 
distant organs (Chin et al., 2006; Gray-Schopfer et al., 2007). This model is in agreement with 
the tumor clonal evolution model (Nowell, 1976), which hypothesizes that cancer evolves 
from a poorly to a highly metastatic phase through accumulation of molecular alterations 
(mutations and/or epigenetic changes) that enhance proliferative and invasive potential of 
tumor cells, and that would promote lineal progression from RGP to VGP to metastasis 
(Miller and Mihm, 2006). 
Even though the classification of melanomas according to the thickness of the lesion is one 
of the most widely used methods for the diagnosis and prognosis of melanoma (Fecher et al., 
2007), frequently there are lesions whose thickness does not correlate with their actual 
aggressiveness and metastatic outcome (Lomuto et al., 2004; Slingluff et al., 1988). Besides, 
this model does not offer either convincing explanations for the heterogeneity found in 
metastatic melanoma cells, nor for the persistent failure of anti-melanoma therapies. 
Consequently, in the last decade researchers have aimed to establish a molecular 
classification of melanoma utilizing gene expression profiling tools (Fecher et al., 2007; Hoek, 
2007; Hoek, 2009). A number of studies have been able to classify collections of melanoma 
cell lines or biopsies into groups differing in their aggressiveness and metastatic potential, 
confirming the large heterogeneity of melanoma and the importance of the microenvironment 
in determining gene expression programs of melanoma cells and progression to metastasis 
(Bittner et al., 2000; Haqq et al., 2005; Hoek, 2007; Pavey et al., 2004). 
One of these studies, by means of genome-wide gene expression analysis and functional 
assays, described that most melanoma cell lines could be categorized according to their gene 
expression profile into two extreme phenotypes, proliferative or invasive (Hoek et al., 2006). 
The proliferative gene signature encompasses a number of melanocytic lineage genes such 
as microphthalmia-associated transcription factor (MITF) and some of its targets, while the 
invasive phenotype signature is defined by suppressed expression of proliferative genes in 
favor of others related to the modification of the tumor microenvironment (Hoek et al., 
2006). Based on this and other studies a new melanoma progression model was proposed, 
which takes into account the heterogeneous nature of melanoma and the key role of the 
tumor microenvironment (Carreira et al., 2006; Goodall et al., 2008; Hoek, 2009; Hoek et al., 
2008; Hoek et al., 2006). This new model, referred to as phenotype switching, considers 
metastatic potential split into two mutually exclusive and reversible states, proliferative and 
invasive, and hypothesizes that melanoma progression is driven by the reversible switching 
between these two phenotypes (Hoek, 2009). A primary lesion would be initially composed 
of proliferative phenotype cells. Signals from the microenvironment, such as hypoxia or 
inflammation, would make some cells switch their gene signature to become invasive, 
which would allow them to escape from the primary tumor and eventually reach and 
colonize a foreign distant organ. There, signals from the new environment would reprogram 
cells back to the proliferative signature, ultimately developing metastases (Carreira et al., 
2006; Goodall et al., 2008; Hoek et al., 2008). 
The phenotype switching model also relies on human melanoma high plasticity and ability 
to be reprogrammed. As mentioned before, an example of the high plasticity of melanoma 
cells is vasculogenic mimicry (Seftor et al., 2002). Some aggressive melanoma cells have been 
found to express molecular markers typical of other cell types, such as endothelial cells, 
which presumably allow melanoma cells to form vasculogenic networks that mimic blood 
vessels, and that could serve as an alternative route of escape for melanoma cells. This 
phenomenon has also been reported to occur in vivo in aggressive human melanoma 
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samples, and correlates with poor outcome (Folberg et al., 2000; Hendrix et al., 2003; 
Maniotis et al., 1999). Furthermore, poorly aggressive melanoma cells can be reprogrammed 
to highly aggressive and invasive by exposing them to matrices preconditioned by more 
aggressive melanoma cells, highlighting the importance of the tumor microenvironment in 
driving melanoma progression (Postovit et al., 2006; Seftor et al., 2006). 
3.2 Melanoma invasion 
Primary melanoma patients can be usually cured by surgical removal of the tumor when 
detected early, but most of the times melanoma rapidly metastasizes with a poor outcome 
(Gray-Schopfer et al., 2007). Therefore it is essential to understand the mechanisms by which 
melanoma cells escape from the primary tumor and spread and invade other organs, in 
order to develop improved therapies that increase patient survival rates. Following there is 
a brief summary detailing some key molecules involved in melanoma migration/invasion 
and metastasis; interested readers are suggested to read topic reviews elsewhere (Gaggioli 
and Sahai, 2007; Uong and Zon, 2010). 
MITF plays a pivotal role in melanocyte and melanoma biology, as it is involved not only in 
the control of migration and invasion, but also in proliferation, survival, and differentiation 
of melanocytic cells (Levy et al., 2006). The fine tuning of MITF activity enables melanoma 
cells to switch between a proliferative (high MITF) or invasive (low MITF) state, while very 
high levels promote differentiation and complete absence of MITF is incompatible with 
survival (Carreira et al., 2006; Gray-Schopfer et al., 2007). 
Additionally, a number of growth factors and cytokines are upregulated as melanoma 
becomes more invasive, such as hepatocyte growth factor (HGF), TGF-β, IL-8, Nodal and 
several members of fibroblast growth factor (FGF) family (al-Alousi et al., 1996; Albino et al., 
1991; Topczewska et al., 2006). In addition to the autocrine effect on melanoma cells 
themselves upregulating cell motility genes, these factors are thought to have also paracrine 
pro-invasive effects, since they can signal to other cell types of the microenvironment, such 
as fibroblasts, to produce more pro-invasive molecules, like tenascin C and HGF (De Wever 
et al., 2004). On the other hand, HGF receptor c-Met has also been shown to have pro-
invasive effects in melanocytes and melanoma cells (McGill et al., 2006). 
Melanoma inhibitory activity (MIA) protein is highly expressed in malignant melanomas 
but not in melanocytes (Bosserhoff, 2005). Several studies have shown that MIA enhances 
melanocyte and melanoma migration and invasion (Tatzel et al., 2005), and additionally 
have suggested a central role for MIA in early melanoma development by regulating 
important melanoma-related pathways (Bosserhoff, 2005). 
The Snail family transcription factors Snail and Slug have also increased activity in 
melanoma, since they downregulate the expression of keratinocyte-interacting surface 
molecules, such as E-cadherin and occluding, while upregulate N-cadherin, favoring 
interaction with stromal cells and not keratinocytes (Gaggioli and Sahai, 2007; Kajita et al., 
2004). Furthermore, Snail co-ordinately upregulates the expression of cell motility genes 
including matrix metalloproteinase (MMP)- 2, secreted protein acidic and rich in cysteine 
(SPARC), tissue inhibitor of metalloproteinases 1 (TIMP-1) and RhoA (Kuphal et al., 2005). 
Recently several studies have highlighted that melanoma cells also display a high plasticity 
regarding their cell motility. Melanoma cells can migrate and invade with different modes 
of movement that presumably allow them to adapt to varying microenvironments (Sahai 
and Marshall, 2003; Sanz-Moreno et al., 2008). The main switches of these melanoma cell 
motility programs are Rho-GTPases family members Rac and Rho (Sanz-Moreno et al., 2008), 
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which are overexpressed in cancer (Sahai, 2005). Rac promotes a more elongated shape that 
requires matrix metalloproteinases in order to invade, while RhoA favors a rounded 
morphology and a movement less dependent on proteases (Sanz-Moreno et al., 2008). On the 
other hand, MMPs are upregulated in invasive melanoma and they are thought to promote 
melanoma dissemination, probably through different mechanisms since different MMPs are 
thought to have pro- or anti-invasive effects (Overall and Lopez-Otin, 2002). 
3.3 PEDF as a brake for melanoma progression 
As previously mentioned, the antiangiogenic activity of PEDF prompted the study of its 
potential antitumor effects. We (Fernandez-Garcia et al., 2007; Garcia et al., 2004) and others 
(Abe et al., 2004; Doll et al., 2003; Ek et al., 2006b) described a complex mechanism underlying 
the potent inhibition of melanoma metastasis by PEDF. PEDF’s antitumor activity in 
melanoma and other tumors is based on its dual action on the tumor microenvironment and 
on the tumor cells themselves (Fernandez-Garcia et al., 2007). PEDF inhibits tumor 
angiogenesis by means of induction of apoptosis on endothelial cells and modulation of the 
angiogenic profile of melanoma cells, eventually destroying the main source of nutrients to 
the primary tumor as well as one of the main routes of dissemination to distant organs. 
Additionally, PEDF exerts a potent inhibitory action on melanoma cells, inducing apoptosis 
under stress conditions (such as absence of growth factors or detachment from the 
extracellular matrix) and abrogating migration and invasion. As a whole, PEDF 
overexpression in melanoma cells leads to a decrease in primary tumor growth and an 
inhibition of lung metastasis formation (Fernandez-Garcia et al., 2007; Filleur et al., 2009). 
In the previous section we described that PEDF is produced by low aggressive melanomas. 
Given that cutaneous melanoma develops from skin melanocytes, two questions soon arise: 
i) are normal melanocytes expressing this factor endogenously?, ii) if so, which could be the 
role of PEDF in normal melanocytic cells? By means of assessing a large collection of 
primary cultures of cutaneous melanocytes and other cell types of the skin we found that 
melanocytes secrete very high levels of PEDF comparable to other cell types known to 
express this factor (Orgaz et al., 2009). In agreement with previous reports, dermal 
fibroblasts also express high levels of PEDF, which has been described to be involved in the 
control of their proliferative potential (Francis et al., 2004; Tresini et al., 1999); additionally, 
PEDF secreted by fibroblasts could also play a role in maintaining a correct vascularization 
of the skin. In contrast, PEDF is expressed at very low levels by epidermal keratinocytes or 
microvascular endothelial cells (Orgaz et al., 2009). 
In melanocytes, PEDF is one of the players involved in the regulation of their proliferation 
and migratory ability (Fig. 1). PEDF silencing in primary melanocytes leads to an increase in 
their migration and invasion, as well as a moderate augment in their growth rate (Orgaz et 
al., 2009). Melanocytes arise from highly migratory embryonic neural crest progenitors, and 
therefore display an enormous migratory potential (Gupta et al., 2005; Zbytek et al., 2008) 
that must be tightly controlled in the skin (Hsu et al., 2002). In addition to the regulatory 
signals from adjacent keratinocytes, an additional brake to their uncontrolled dissemination 
could be self-imposed within melanocytes by expressing high levels of PEDF themselves. As 
suggested for the fibroblasts, melanocytes could be also participating in the maintenance of 
appropriate angiogenesis in the skin by secreting this potent antiangiogenic factor, taking 
into account previous studies reporting an excessive vascularization of multiple organs 
upon PEDF knockdown (Doll et al., 2003). Additional paracrine actions on other cell types, 
keratinocytes for instance, remain to be investigated. 
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Importantly, recent evidence points to a possible role of PEDF in melanocytic lineage-
specific functions, such as pigment production. Melanocytes utilize specialized membrane 
vesicles called melanosomes to synthesize, store and deliver melanin to the cell membrane, 
eventually being transferred to surrounding keratinocytes (Barral and Seabra, 2004; Lin and 
Fisher, 2007). In a recent study we have found that PEDF overexpression in melanoma cell 
lines modulates the expression of Rab27A and melanophilin, two regulators of melanosome 
trafficking and melanin transfer (Orgaz et al., 2011). Accordingly, previous reports had 
proposed the involvement of PEDF in pigment production, as PEDF was found in immature 
melanosomes of melanoma cells (Chi et al., 2006) and it was also shown to induce tyrosinase 
expression (Abul-Hassan et al., 2000) and melanosome maturation in RPE cells (Malchiodi-
Albedi et al., 1998). However, further studies are warranted in order to elucidate the 
functional role of PEDF in melanin production and/or secretion. 
 
 
Fig. 1. Regulation of expression of PEDF during melanoma progression and functional 
effects in melanocytes and melanoma cells. Skin melanocytes express high levels of PEDF, 
which contribute to restrict their migratory and proliferative ability, and to regulate skin 
vascularization. In melanoma, PEDF expression is regulated by yet unidentified 
mechanisms that determine high levels in proliferative phenotype cells, and low levels in 
invasive phenotype cells. Melanoma progression is driven by switching between 
proliferative and invasive phenotypes, which involves reprogramming of PEDF and 
heterogeneous expression of this factor in primary and metastatic melanomas 
The high expression of PEDF in skin melanocytes and its antitumor effects in melanoma 
raise the question whether PEDF expression could be modulated during melanoma 
development as it takes place in other types of cancer. However, defining melanoma 
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progression is a complex task. Therefore, we utilized different approaches in order to 
interrogate levels of PEDF during melanoma malignization (Orgaz et al., 2009). When taking 
into account histopathological criteria (classical model of melanoma progression), PEDF 
expression is greatly diminished or lost in metastasis-derived melanoma cell lines compared 
to cell lines established from RGP or VGP tumors, even though we found a significant 
variability in PEDF levels across melanoma cell lines. Accordingly, PEDF expression is 
lower in metastatic melanoma biopsies compared to primary melanomas (Orgaz et al., 2009; 
and unpublished data) (Fig. 1). 
This first analysis was expanded taking advantage of the vast collection of publicly available 
gene expression data from large series of melanoma cell lines and primary cultures of 
melanocytes. Firstly, we confirmed the downregulation of PEDF expression in melanoma 
compared to primary melanocytes (Fig. 1) (Hoek, 2007; Orgaz et al., 2009). When classifying 
a number of series of melanoma cell lines regarding their gene expression profile into 
proliferative or invasive phenotype, we found that there is a significant decrease of PEDF 
expression in invasive phenotype melanoma cell lines. This suggests again an inverse 
correlation between melanoma aggressiveness and invasiveness, and expression levels of 
PEDF (Orgaz et al., 2009). 
Furthermore, expression of PEDF is subject to certain plasticity and can be reprogrammed 
during the metastatic progression of melanoma. We utilized paired cell lines isolated from 
the same metastasis of a cutaneous melanoma patient, and that display extreme phenotypes, 
poorly or highly aggressive (Seftor et al., 2005). Only the poorly aggressive melanoma cell 
line expresses PEDF at high levels comparable to those of melanocytes, while it is 
undetectable in the highly aggressive cell line. The heterogeneity of PEDF expression is also 
found in vivo when analyzed in biopsies from dermal or lymph node melanoma metastases. 
Most of the biopsies from metastases are negative for PEDF, but when positive they display 
a heterogeneous staining pattern of PEDF expression (Orgaz et al., 2009). Both observations 
strongly suggest that PEDF expression could be reprogrammed during the metastatic 
process in melanoma, in the context of the phenotype switching model, being expressed 
only by the poorly aggressive subpopulation of tumor cells (Fig. 1). Regulatory signals from 
the tumor microenvironment could be responsible, at least in part, for this switching in 
PEDF expression. As an example, primary melanocytes grown on collagen matrix 
preconditioned by a highly aggressive melanoma cell line display decreased PEDF 
expression levels compared to melanocytes grown on untreated matrix (Seftor et al., 2005). 
The inverse correlation between melanoma aggressiveness and PEDF expression raises 
additional important questions. Firstly, what is the functional significance of PEDF modulation 
during melanoma progression? We addressed this by silencing endogenous PEDF 
expression in several melanoma cell lines utilizing short hairpin RNAs specific to PEDF 
delivered by lentiviral transduction. As in melanocytes, endogenous PEDF restricts the 
migratory and invasive ability of melanoma cells, which greatly translates in vivo: we found 
that PEDF inhibits spontaneous lung colonization by melanoma cells as well as formation of 
spontaneous lung metastases from a primary tumor (Orgaz et al., 2009). Inhibition of 
spontaneous metastases formation by PEDF is particularly noteworthy, since it highlights 
that this factor also restricts the initial steps of the metastatic cascade, local invasiveness 
from the primary tumor and intravasation. Additionally, PEDF impinges on vasculogenic 
mimicry ability of melanoma cells (Fig. 1), diminishing the formation of vasculogenic 
networks by melanoma cells both in vitro on collagen matrices and in vivo in the lung 
parenchyma after tail vein injection into immunocompromised mice (Orgaz et al., 2009). 
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Therefore, in the model that we propose reprogramming of PEDF expression is important 
for the switching between proliferative and invasive phenotypes that are thought to drive 
metastatic progression of melanoma. Unknown mechanisms so far determine that PEDF 
expression is high in proliferative phenotype primary tumor cells, where it restricts migratory 
and invasive abilities, angiogenic potential and vasculogenic mimicry, as a whole leading to 
a diminished metastatic potential. However, loss of PEDF helps melanoma cells to acquire 
an invasive phenotype essential to disseminate and colonize distant organs. There, some 
metastatic cells would be reprogrammed by signals from the new microenvironment toward 
proliferative phenotype cells, switching back to express PEDF again. Eventually these cells 
will develop micrometastases and macrometastases, where additional reprogramming 
events will take place leading to a metastatic lesion heterogeneous for PEDF expression. 
Additionally, mechanisms yet to be described determine a loss of PEDF expression in fully 
developed melanoma metastases (Fig. 1). 
Despite the knowledge we have gathered regarding PEDF modulation in melanoma, 
important questions still remain to be resolved. First of all, which are the regulators of PEDF 
during melanoma progression? Elucidating the mechanisms that promote or repress PEDF 
expression would help better understand how PEDF changes in the course of transformation 
and malignant progression of melanoma. Our results suggest that PEDF expression could be 
modulated by two general types of mechanisms, reprogramming events and loss of 
expression. 
Assessing PEDF expression during maturation and migration of neural crest precursors 
toward epidermis could allow investigating the relationship between migratory potential 
and differentiation state and PEDF expression in a physiological context. Eventually this 
could also help identify possible factors involved in reprogramming PEDF in the different 
environments that neural crest precursors encounter in their way toward epidermis. Some 
of these factors are likely to be responsible for modulating PEDF expression in melanoma 
cells, given that tumor cells frequently activate signaling pathways and utilize regulatory 
mechanisms typical of progenitor cells. 
Signals from the microenvironment such as hypoxia and inflammation are thought to 
reprogram and switch melanoma cells toward an invasive phenotype, and therefore, could 
be responsible for the downregulation of PEDF during melanoma progression. As a matter 
of a fact, earlier reports described that PEDF expression is decreased by hypoxia in 
retinoblastoma (Dawson et al., 1999) and RPE (Notari et al., 2005). Additionally, transcription 
factors that drive and are at the core of each phenotype gene signature could be direct 
regulators of PEDF expression. MITF is an appealing candidate, since it is a key factor in 
melanoma and melanocyte biology (Levy et al., 2006) with anti-invasive effects and whose 
expression is tightly associated with the proliferative phenotype (Carreira et al., 2006; Hoek 
et al., 2008). Similar to PEDF, some studies have reported a trend toward loss of MITF 
expression in metastases compared to primary melanomas (Carreira et al., 2006; Goodall et 
al., 2008). 
Additionally, genetic and epigenetic mechanisms could lead to a loss of PEDF expression as 
melanoma evolves to metastatic. The expression of a number of angiogenesis regulators in 
cancer is controlled by gain of expression of oncogenes and loss of tumor suppressors 
(Bouck, 1990). PEDF is a direct target of p53-related p63 and p73 proteins in colorectal 
carcinoma (Sasaki et al., 2005). In melanoma, TA-p73 isoform has been recently described to 
inhibit anchor independent growth through KCNK1 protein, whose expression decreases in 
melanoma compared to normal skin (Beitzinger et al., 2008). Therefore it would be 
www.intechopen.com
Pigment Epithelium-Derived Factor –  
An Angiostatic Factor with a Broader Function in Melanoma 
 
155 
interesting to assess whether p73 is implicated in regulating PEDF expression during 
melanoma progression. Human melanomas display either oncogenic NRAS (20% 
melanomas) or BRAF (50-70%), thought to be responsible of the initial transformation of 
melanocytes, uncoupling cell growth from external mitogenic stimuli (Chin, 2003; Chin et al., 
2006). However, by means of an analysis of publicly available microarray data from 
melanoma cell lines, we did not observe a significant correlation between PEDF expression 
levels and BRAF or NRAS mutation status (unpublished data). Finally, loss of expression of 
PEDF could occur upon epigenetic silencing of its promoter. Maspin, another member of 
Serpin family with anti-invasive and anti-tumor activities, is expressed at high levels in 
melanocytes but it is silenced in naevi and melanomas by epigenetic mechanisms (Denk et 
al., 2007). 
Although molecular aspects of the mechanism of action of PEDF on endothelial cells or 
neural derived cells have been described little is known about the molecular mechanisms 
underlying PEDF´s actions in melanoma, particularly in the inhibition of invasion and 
metastasis.  
Interestingly, a recent study by us utilizing a gene expression analysis upon PEDF 
overexpression in melanoma cell lines has started to reveal some factors and pathways that 
could be mediating PEDF antimetastatic effects (Orgaz et al., 2011). PEDF downregulates 
several key promigratory and proangiogenic factors such as IL-8, TGF-α and TGF-β, as well 
as a number of proteases and extracellular matrix proteins, like collagen IV, that could 
account for the lesser invasive ability and angiogenic potential of melanoma cells expressing 
PEDF. Additionally, PEDF modulates genes previously involved in melanoma progression 
toward a trend in agreement with decreased aggressiveness and invasiveness, such as 
factors from the Notch (Pinnix and Herlyn, 2007) or Wnt (Weeraratna, 2005) pathways, as 
well as FGF13 (Hoek et al., 2004), insuling-like growth factor binding protein 3 (IGFBP3) (Xi 
et al., 2006) or inhibin beta A (INHBA) (Hoek et al., 2006), among many others. Interestingly, 
a number of melanoma markers with increased levels upon melanoma malignization are 
predominantly downregulated by PEDF overexpression, such as MIA or S100-β (Deichmann 
et al., 1999; Utikal et al., 2007). 
4. Therapeutic applications of pigment epithelium derived-factor 
4.1 Biochemical features of PEDF 
Therapeutic applications of PEDF are closely related to the cellular niches where this factor 
is produced and to the multiplicity of cellular functions and activities ascribed to this 
secreted serpin family member. 
SERPINs are a large superfamily of genes that codes for serine protease inhibitors in 
mammals (Tombran-Tink et al., 2005). These proteins are able to control several processes 
such as blood coagulation, complement activation and extracellular matrix remodelling 
(Filleur et al., 2009; Tombran-Tink et al., 2005). However, there is a small number of serpin 
family members with non-inhibitory protease activity, among which is included PEDF 
(SERPINF1) (Becerra et al., 1995; Lawrence et al., 1990; Steele et al., 1993). The inhibitory 
activity against proteinases resides in a domain called reactive centre loop (RCL). The 
reason why PEDF lacks protease inhibitory capability is due to the presence in the RCL of 
several proline residues preceding the cleavage site (Simonovic et al., 2001). 
Amino acid analyses indicate that PEDF shares considerable sequence homology with other 
members of the serpin family (Steele et al., 1993); however, residues 40-67, at the N-terminal 
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(N-ter) region, and residues 277-301 at C-terminal (C-ter) are specific to PEDF. This feature 
suggests that these residues could be involved in maintaining the distinct structure of PEDF 
in these regions or in determining specific functions of this non-inhibitory serpin (Tombran-
Tink et al., 2005; Xu et al., 2006). Tombran-Tink and collaborators also compared sequence 
homology of PEDF protein among different species and analyzed structural homology. They 
found a high degree of conservation in the leader sequence, responsible for protein 
secretion, a C-ter glycosilation site, and four specific regions: two domains present at N-ter 
region, corresponding to residues 40-67 and 78-95; and other two regions, 277-301 and 384-
415, located at C-ter of the protein (Tombran-Tink et al., 2005). 
PEDF was initially isolated from conditioned medium of human fetal RPE cells and 
identified as a neurotrophic factor (Tombran-Tink and Johnson, 1989), although further 
studies showed that it is widely expressed throughout fetal and adult tissues (Ek et al., 
2006b). This broad expression is suggestive of a general and relevant function of PEDF in 
mammals. PEDF is also known as EPC-1 (early population doubling cDNA-1), and has been 
shown to participate in cell cycle regulation, initially in fibroblasts (Pignolo et al., 1993; 
Tombran-Tink and Johnson, 1989; Tombran-Tink et al., 1995) and later in other cell types like 
endothelial cells (Duh et al., 2002; Hutchings et al., 2002). PEDF’s cell cycle regulatory 
function requires the presence of a putative nuclear localization sequence (residues 141-151) 
that is highly conserved in SERPINF1 among different species, and could mediate PEDF 
translocation to the nucleus (Tombran-Tink et al., 2005). One of the most relevant functional 
characteristics of PEDF is its antiangiogenic activity, being considered as the most potent 
natural inhibitor of physiological and pathological angiogenesis (Dawson et al., 1999). PEDF 
is also a very effective neurotrophic factor that induces cell differentiation, cell survival, and 
protection from cell death in many cell types of the nervous system. PEDF prevents 
degeneration of retinal neurons that are exposed to transient ischemic reperfusion (Ogata et 
al., 2001), and also protects other regions of the brain and spinal cord from the damaging 
effects caused by oxidative stress and glutamate toxicity (Bilak et al., 1999; Cao et al., 1999; 
DeCoster et al., 1999; Taniwaki et al., 1995). It has been shown the implication of NFkB in all 
these processes, which induces the expression of neurotrophic factors and anti-apoptotic 
genes that participate in the control of cell survival, proliferation and death (Barnstable and 
Tombran-Tink, 2004; Yabe et al., 2001). Neurotrophic activity has been mapped to the N-ter 
region of PEDF, encompassing residues Val58-Thr101 (Simonovic et al., 2001). This region is 
involved in binding to a putative plasma membrane receptor in cerebellar granule neurons 
and retinoblastoma cells (Alberdi et al., 1999). PEDF is also secreted by ependymal and 
endothelial cells from the subventricular zone of the brain, where it promotes the self-
renewal of adult neural stem cells (Andreu-Agullo et al., 2009; Ramirez-Castillejo et al., 2006). 
Furthermore, PEDF presents three phosphorylation sites located in Ser24, Ser114 and Ser227, 
and the regulation of their phosphorylation state modulates the switch of PEDF’s function 
from neurotrophic (Ser24 and Ser114 phosphorylated) to angiangiogenic (Ser227 phosphorylated) 
(Becerra, 2006). 
In order to better understand the mechanism of action of PEDF, it was necessary to identify 
the structural domains responsible for each of its described biological functions. Two major 
epitopes were identified at the N-ter region of PEDF: 34-mer peptide (residues 24-57) 
responsible of the antiangiogenic and pro-apoptotic actions of PEDF; and a second epitope, 
44-mer peptide (residues 58-101), which induces neuronal differentiation of retinoblastoma 
cells (Filleur et al., 2005) and plays a neurotrophic role in many neuronal cell types (Bilak et 
al., 2002). There are another two highly conserved smaller epitopes, one upstream 34-mer, 
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the TGA epitope, and an internal fragment of 44-mer, referred to as ERT. Filleur and 
collaborators showed in vivo that the epitopes TGA and the complete 34-mer inhibit tumor 
angiogenesis in prostate adenocarcinoma by inducing apoptosis of endothelial cells and 
blocking endothelial cell migration. Curiously, ERT despite of being located inside the 
neurotrophic 44-mer peptide, also presents antiangiogenic activity in prostate 
adenocarcinoma. Complete 44-mer is able to induce neurite outgrowth in Y-79 
retinoblastoma cell line and causes apoptosis of endothelial cells, blocking migration and 
angiogenesis (Filleur et al., 2005). In a more recent study, smaller regions of 34-mer epitope 
(named P14, P18 and P23, according to their respective length) were tested for 
angioinhibitory activity in vitro and in vivo. P14 and P23 display antiangiogenic activity in 
vitro (both blocking endothelial chemotaxis, and inducing apoptosis in the case of P23), but 
not in vivo; while P18 is a more potent antiangiogenic peptide than 34-mer in prostate 
cancer, being able to block bFGF and VEGF-dependent angiogenesis in the in vivo cornea 
neovascularisation assay (Mirochnik et al., 2009). Another study by Ek and colleagues 
identified other small peptides with antitumoral activity in an orthotopic osteosarcoma 
model. They generated six 25-mer peptides along the functionally distinct regions of PEDF 
characterized so far. Residues 78-102 inhibit proliferation, whereas residues 90-114 stimulate 
adhesion of PEDF to type I collagen. Furthermore, residues 387 to 411 inhibit invasion of 
osteosarcoma cells in vitro and residues 40-64 promote osteogenic differentiation (Ek et al., 
2007). 
The multifunctional character of PEDF and the evidence of the different roles displayed 
depending on the cell type, suggest that PEDF could be acting through distinct domains 
recognized by several specific receptors. The identification of these putative receptors and 
the characterization of the binding affinity of each functionally identified peptide toward 
them could make a breakthrough in the understanding of PEDF’s mechanism of action and, 
therefore, the possibility of its therapeutic use in multiple pathological contexts. 
4.2 PEDF receptors 
Several studies have characterized the affinity of PEDF for the surface of human 
retinoblastoma cells, cerebellar granular neurons (Alberdi et al., 1999), motor neurons (Bilak 
et al., 2002), neural retina (Aymerich et al., 2001) and endothelial cells (Yamagishi et al., 2004). 
PEDF could be sequestered in the extracellular matrix based on ionic interactions with 
sulphated (heparin, heparin sulfate and condroitin sulfate) (Alberdi et al., 1998), and non-
sulfated (hyaluronan) (Becerra et al., 2008) glycosaminglycans and type I collagen (Meyer et 
al., 2002). In order to identify the potential receptor(s) of PEDF, Simonovic and collaborators 
carried out a three-dimensional study of PEDF, and identified an asymmetric charge 
distribution, with a high acidic region located at C-ter and basic amino acids at opposite 
region of PEDF protein (Simonovic et al., 2001). This basic region is involved in the binding 
of PEDF to heparin through three clustered basic amino acid residues, Lys146, Lys147 and 
Arg149. Moreover, Asp256, Asp258 and Asp300 residues present in the acidic region of PEDF are 
crucial to type I collagen binding (Meyer et al., 2002; Yasui et al., 2003). 
Using the 34-mer and 44-mer epitopes it was possible to propose the existence of two 
distinct putative receptors for PEDF. These epitopes are able to bind the surface of 
endothelial and prostate cells, but they do not compete for receptor binding (Filleur et al., 
2005). This result suggests the existence of two PEDF receptors with different functions: 
PEDF-RN, that interacts with 44-mer epitope and regulates the neurotrophic and 
neuroprotective activities of PEDF; and PEDF-RA, which is involved in blocking 
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angiogenesis by binding to 34-mer epitope (Fig. 2). The differential expression of these two 
putative PEDF receptors in the diverse cell types analyzed supports the idea of distinct 
functions for each receptor type. PEDF-RN is an 80-kDa receptor, which is located on the 
surface of human retinoblastoma cells, neural retina, cerebellar granular and motor neurons, 
whereas PEDF-RA is a 60-kDa receptor specifically present on endothelial cells (Filleur et al., 
2009). 
 
 
Fig. 2. Three-dimensional structure of PEDF, small peptides derived from PEDF and 
receptors. Crystal structure of PEDF molecule showing the location of 34-mer and 44-mer 
peptides. PEDF could be sequestered in the extracellular matrix by ionic interactions with 
type I collagen and glycosaminglycans. 34-mer, TGA and ERT peptides display 
antiangiogenic action through their bind to 60-kDa receptor (PEDF-RA, proposed as the non-
integrin 67-kDa laminin receptor) in endothelial cells. 34-mer also has the capability to 
induce apoptosis in tumor cells. 44-mer and ERT peptides present a neurotrophic action 
through their binding to the TTS-2.2/ (PLA2) ξ receptor (putatively identified as the PEDF-
RN) in several cell types. Abbreviations: 67LR: Non-Integrin 67-kDa laminin receptor; TTS-
2.2/(PLA2)ξ: Transport secretion protein 2.2/Independent phospholipase A2; Y79: human 
retinoblastoma cell line; CGN: cerebellar granular neurons 
www.intechopen.com
Pigment Epithelium-Derived Factor –  
An Angiostatic Factor with a Broader Function in Melanoma 
 
159 
Further studies identified on the surface of the retina and human immortalized 
retinoblastoma cells (ARPE-19) the human Transport Secretion Protein 2-2 (TTS-2.2) 
/Independent phospholipase A2 (PLA2)ξ (also known in mice as adipose triglyceride lipase-
ATGL, desnutrin, and patatin-like phospholipase domain containing protein-PNPLP2), an 
important lipase involved in triglyceride metabolism, as a specific PEDF receptor (Notari et 
al., 2006). The phospholipase A2 domain of this receptor releases bioactive fatty acids that 
function as second messengers. Therefore, depending on the lipid released, this receptor 
could activate different signal transduction pathways. It is still not fully demonstrated if the 
80-kDa (PLA2)ξ receptor is the previously identified PEDF-RN receptor (Fig. 2). 
Recently, a new receptor for PEDF has been identified, the non-integrin 67-kDa laminin 
receptor (67LR) (Bernard et al., 2009), which may be related to the 60-kDa receptor 
previously reported in endothelial cells (Yamagishi et al., 2004). This hypothesis is supported 
by the observation of antiangiogenic effects (inhibition of endothelial cell migration and 
induction of endothelial cell apoptosis) when 34-mer epitope binds to 67LR and the 
previously described 60-kDa receptor. 
However, whether these characterized receptors are expressed on the surface of 
melanocytes and melanoma cells to mediate multiple PEDF’s biological activities, and 
whether other unknown melanocytic lineage-specific receptors could play a role in 
translating PEDF’s effects, remains to be investigated. 
4.3 Therapeutic prospects for PEDF 
During the last two decades many groups have described PEDF as a multifunctional protein 
that plays effective neuroprotective and antiangiogenic activities. The wide diversity of 
PEDF functions, along with the fact that it is an endogenous molecule, makes PEDF a 
unique candidate for a therapeutic agent in many diseases. 
Several studies have already shown the role of PEDF in various pathological conditions 
such as ocular and chronic inflammatory diseases, atherosclerosis and diabetes. Moreover, 
several groups have demonstrated, in vivo and in vitro, the antitumor and antimetastatic 
potential of PEDF. They described the capability of PEDF to induce tumor cell differentiation 
in neuroblastoma (Crawford et al., 2001) and prostate cancer (Filleur et al., 2005); a direct 
tumor suppression action in osteosarcoma (Takenaka et al., 2005), melanoma (Abe et al., 
2004; Garcia et al., 2004) and prostate cancer (Filleur et al., 2005; Guan et al., 2007); and its 
angiostatic action in a wide number of tumor types that include, among others, melanoma 
(Abe et al., 2004; Garcia et al., 2004; Orgaz et al., 2009; Yang and Grossniklaus, 2010). 
The use of PEDF as a therapeutic agent in the clinic requires deeper knowledge of its 
biological effects and underlying molecular mediators. An important feature is the 
development of effective therapeutic agents based on the optimum combination of 
biological activities beneficial for each specific pathological context, together with the 
development of optimum delivery systems to allow proper targeting and stability during 
treatment. One of the possibilities is the use of recombinant full-length PEDF protein 
(rPEDF) produced in human embryonic kidney cells. Also, as PEDF is secreted at high levels 
by RPE cells, endogenous PEDF protein can be purified from the conditioned medium of 
RPEs. rPEDF has been successfully tested in vitro and in vivo in osteosarcoma (Takenaka et 
al., 2005), prostate cancer (Doll et al., 2003) and neuroblastoma (Crawford et al., 2001). Due to 
its endogenous nature, short-term treatment would not lead to any immune response after 
systemic administration. However, the main disadvantage of this strategy is the 
susceptibility of rPEDF to cleavage by proteases, and therefore a limited bioavailability. 
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PEDF is a protein that is 418 amino acids in length. Filleur and collaborators elucidated that 
two small fragments of PEDF, 34-mer and 44-mer, were able to display the antiangiogenic 
and neurotrophic roles (respectively) as the complete protein (Filleur et al., 2005). Shorter 
peptides improve the stability and delivery, and reduce the possibility of being recognized 
by the immune system. However, the use of rPEDF or small peptides derived from 
functionally active regions requires a systemic distribution; and therefore due to the 
antiangiogenic activity of this factor or derived peptides, its presence in plasma could have 
unexplored side effects on physiologic vascularization during the menstrual cycle and 
wound healing (Ek et al., 2006a). 
An alternative strategy that has been widely tested by a number of groups in mouse models 
of cancer is the use of viral vectors for the delivery of either full length PEDF or small 
peptides derived from the diverse functional regions identified. Gene transfer using viral or 
plasmid vectors is an attractive tool for human cancer gene therapy. Several studies have 
used this strategy in different types of cancer, such as pancreatic cancer (Hase et al., 2005), 
neuroblastoma (Streck et al., 2005), prostate cancer (Guan et al., 2007) and melanoma (Abe et 
al., 2004; Garcia et al., 2004; Orgaz et al., 2009; Yang and Grossniklaus, 2010), with a reduction 
of primary tumor size and number of metastases after PEDF delivery. 
In melanoma, Abe’s group and us were the first to describe the antitumor effect of PEDF in 
vitro and in vivo in malignant melanoma cell lines (Abe et al., 2004; Garcia et al., 2004). To this 
aim, Abe and collaborators overexpressed PEDF by transfection of G361 melanoma cell line 
and observed in nude mice a reduction of tumor angiogenesis and an almost complete 
inhibition of G361 growth in melanoma xenografts. These effects are the result of 
suppression of tumor angiogenesis and induction of Fas ligand-dependent apoptosis in 
tumor cells (Abe et al., 2004). We used a retroviral strategy to transduce the human 
melanoma cell line UCD-Mel-N, which does not express significant levels of endogenous 
PEDF. We observed a considerable inhibition of primary tumor growth in subcutaneous 
xenotransplants in immunocompromised mice and a complete abrogation of lung 
metastases formation in the tail vein injection model. We demonstrated that the inhibition of 
primary melanoma tumor growth by PEDF is based on selective destruction of immature 
vessels, together with a significant direct induction of apoptosis in melanoma cells. 
Although it was first demonstrated that PEDF inhibits endothelial cell migration and 
induces apoptosis in remodelling endothelium, we showed that PEDF also has direct effects 
on melanoma cells, inhibiting melanoma cell migration and inducing apoptosis under stress 
conditions like absence of growth factors or detachment from the extracellular matrix 
(Garcia et al., 2004). In a recent work we also used a lentiviral transduction strategy to 
silence PEDF in poorly aggressive melanoma cell lines with high expression of endogenous 
PEDF. PEDF knockdown in these melanoma cell lines enables the acquisition of an invasive 
phenotype, showing the critical importance of PEDF for the malignant progression of 
human melanoma (Orgaz et al., 2009). 
Retroviral and lentiviral vectors are attractive tools for human cancer gene therapy and, 
based on their ability to integrate into the genome, they have the potential to achieve long-
term stable expression and maintain therapeutic levels of secreted peptides (Hase et al., 
2005). Both types of virus are able to transduce proliferating cells, although only lentiviruses 
present the advantage of transducing non-dividing cells. This feature is of great advantage 
for gene transfer as a complementary treatment in cancer, due to the fact that chemotherapy 
is only effective in actively proliferative cells, allowing non-dividing cells to be resistant to 
treatment and enabling the development of metastasis. Although viral systems seem to be a 
www.intechopen.com
Pigment Epithelium-Derived Factor –  
An Angiostatic Factor with a Broader Function in Melanoma 
 
161 
promising therapy for cancer and other diseases, there are still some problems and patient 
risks that have to be solved, such as (i) obtaining clinically effective viral titres, (ii) stable 
transgene expression in individuals requiring long-term treatment, and (iii) the risk of de 
novo cancer initiation via recombination within the patient’s cell genome. 
The biological effect of small peptides derived from PEDF retaining different functional 
activities has not yet been explored in melanoma, although it would be very relevant for the 
therapeutic development of PEDF in the context of aggressive melanoma. Also, 
characterization of PEDF’s receptors expressed in melanoma cells is very important in order 
to understand the molecular mechanism of action underpinning the multiple biological 
actions of PEDF on melanoma cells, as well as to develop new therapeutic strategies based 
on the receptors and pathways that mediate PEDF’s actions in aggressive melanoma. 
5. Conclusions 
Collectively, our findings strongly support PEDF as a potent biological modifier that 
effectively halts the metastatic spread of human melanoma by combining distinct functional 
epitopes respectively impinging on the vascular component of the tumor microenvironment 
and on the set of capabilities that a melanoma cell must acquire in order to successfully 
leave its primary site to colonize distant foreign environments. 
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